Q BioMed strikes an early-stage autism deal with Asdera
Q BioMed and Asdera have signed a licensing deal built around a therapeutic intervention for autism spectrum disorder, which seeks to prevent the loss of speech.
Q Biomed
Q BioMed and Asdera have signed a licensing deal built around a therapeutic intervention for autism spectrum disorder, which seeks to prevent the loss of speech.